115844-00-3

Basic information

• Product Name: 4-broMo-2-chloro-5-(trifluoroMethoxy)aniline
• Synonyms: 4-broMo-2-chloro-5-(trifluoroMethoxy)aniline;4-bromo-2-chloro-5-(trifluoromethoxy)benzenamine
• CAS NO: 115844-00-3
• Molecular Formula: C₇H₄BrClF₃NO
• Molecular Weight: 290.4649696
• Mol File: 115844-00-3.mol

Chemical Properties

• Boiling Point: 245.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.812±0.06 g/cm3(Predicted)
• PKA: 0.71±0.10(Predicted)
• CAS DataBase Reference: 4-broMo-2-chloro-5-(trifluoroMethoxy)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-2-chloro-5-(trifluoroMethoxy)aniline(115844-00-3)
• EPA Substance Registry System: 4-broMo-2-chloro-5-(trifluoroMethoxy)aniline(115844-00-3)

Safety Data

• Hazardous Substances Data: 115844-00-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-Bromo-2-chloro-5-(trifluoromethoxy)aniline is used as a building block in organic synthesis for its unique combination of functional groups, which can be utilized in the creation of a wide range of chemical products.
Used in Pharmaceutical Applications:
In the pharmaceutical industry, 4-bromo-2-chloro-5-(trifluoromethoxy)aniline is used as a precursor in the development of new drugs, leveraging its reactive and stable characteristics to form novel medicinal compounds.
Used in Material Sciences:
4-Bromo-2-chloro-5-(trifluoromethoxy)aniline is employed in material sciences for its potential to contribute to the development of new materials with specific properties, such as enhanced stability or reactivity, depending on the application requirements.
The specific uses of 4-bromo-2-chloro-5-(trifluoromethoxy)aniline can vary greatly depending on the field of study or industry, highlighting its adaptability and importance in chemical research and development.

Upstream product

• 116369-25-6 4-bromo-3-(trifluoromethoxy)phenylamine 

Downstream Products

• 1477815-33-0 4-[4-(4-bromo-2-chloro-5-trifluoromethoxyphenylcarbamoyl)piperazin-1-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 1477816-25-3 ((S)-1-{(2S,4S)-2-[4-(5'-chloro-4'-{[4-((S)-2-methylpiperazin-1-yl)piperidine-1-carbonyl]amino}-2'-trifluoromethoxybiphenyl-4-yl)-1H-imidazol-2-yl]-4-methylpyrrolidine-1-carbonyl}-2-methylpropyl)carbamic acid methyl ester 
• 1477815-63-6 (S)-4-[1-(4-bromo-2-chloro-5-trifluoromethoxyphenylcarbamoyl)piperidin-4-yl]-3-methylpiperazinecarboxylic acid tert-butyl ester 
• 1476721-09-1 (R)-4-[5-(2-chloro-4-{2-[(2S,4S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-methyl-pyrrolidin-2-yl]-3H-naphtho[1,2-d]imidazol-7-yl}-5-trifluoromethoxy-phenylcarbamoyl)-pyridin-2-yl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 1374892-55-3 N-(4-bromo-2-chloro-5-trifluoromethoxy-phenyl)-6-fluoro-nicotinamide 
• 1433946-60-1 N-{5-chloro-4'-[2-((2S,4S)-4-methoxy-pyrrolidin-2-yl)-1H-imidazol-4-yl]-2-trifluoromethoxy-biphenyl-4-yl}-6-[(R)-4-(2,2-dimethyl-propionyl)-2-methyl-piperazin-1-yl]-nicotinamide 
• 1433281-16-3 N-(5-chloro-4'-(2-((2S,4S)-4-methylpyrrolidin-2-yl)-1H-imidazol-4-yl)-2-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)-6-((R)-2-methyl-4-pivaloylpiperazin-1-yl)nicotinamide 

Relevant articles and documents

NOVEL INHIBITORS OF HEPATITIS C VIRUS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

NOVEL INHIBITORS OF HEPATITIS C VIRUS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.